Concepedia
Statistics
Publications
9
Citations
945
H-Index
Active since
2019
Affiliations
Wuhan YZY Biopharma (China)(Current)
Huazhong University of Science and Technology
Tongji Hospital
Zhengzhou University
Zhejiang University
Yongxiang Yan is an author at Wuhan YZY Biopharma (China) specializing in cancer immunotherapy, oncology, and immunology.
Publications per year
2019–2024
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Ming Yi, Jing Zhang, Anping Li et al. · Journal of Hematology & Oncology · 2021 · 253 citations · Full text
Medicine, Oncology, Pharmacology +17
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
Ming Yi, Mengke Niu, Jing Zhang et al. · Journal of Hematology & Oncology · 2021 · 178 citations · Full text
Life Sciences, Immunology, Oncology +17
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Ming Yi, Mengke Niu, Yuze Wu et al. · Journal of Hematology & Oncology · 2022 · 178 citations · Full text
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi, Yuze Wu, Mengke Niu et al. · Journal for ImmunoTherapy of Cancer · 2022 · 161 citations · Full text
Pharmacy, Immunology, Oncology +17
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Shengnan Yu, Jing Zhang, Yongxiang Yan et al. · Journal of Experimental & Clinical Cancer Research · 2019 · 100 citations · Full text
1–5 of 9